Marshall Urist Sells 13,684 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 13,684 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $52.75, for a total transaction of $721,831.00. Following the transaction, the executive vice president directly owned 18,197 shares of the company’s stock, valued at $959,891.75. This represents a 42.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $53.06, for a total transaction of $726,073.04.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX traded up $0.49 during trading on Thursday, hitting $53.55. 2,842,883 shares of the stock traded hands, compared to its average volume of 3,648,985. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. The company has a market cap of $30.84 billion, a price-to-earnings ratio of 36.43, a P/E/G ratio of 1.46 and a beta of 0.40. The company has a fifty day moving average price of $48.87 and a two-hundred day moving average price of $43.84. Royalty Pharma PLC has a 52-week low of $32.15 and a 52-week high of $53.59.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.08. The firm had revenue of $631.00 million during the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. As a group, equities analysts predict that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Friday, May 15th. Royalty Pharma’s payout ratio is 63.95%.

Institutional Investors Weigh In On Royalty Pharma

A number of institutional investors have recently added to or reduced their stakes in RPRX. LM Advisors LLC acquired a new stake in Royalty Pharma in the 4th quarter valued at $26,000. Lloyd Advisory Services LLC. acquired a new stake in Royalty Pharma in the 4th quarter valued at $30,000. Smartleaf Asset Management LLC grew its stake in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares during the period. Private Trust Co. NA grew its stake in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 288 shares during the period. Finally, Blue Trust Inc. grew its stake in Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 437 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on RPRX shares. UBS Group lifted their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. JPMorgan Chase & Co. lifted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Morgan Stanley lifted their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Citigroup lifted their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Weiss Ratings cut shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Seven analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $53.71.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.